AGP Limited plans to manufacture and launch Viagra in Pakistan. The company filed this news with the Pakistan Stock Exchange. Consequently, Viagra to be produced in Pakistan from May 2026 subject to regulatory approvals. The board approved an arrangement with an associated entity for this purpose. AGP will act as the Contract Manufacturing Organization for the product. It will also secure marketing rights for commercialization and promotion.

This marks AGP’s entry into a high-value therapeutic segment. The necessary agreements are being finalised between the parties. Therefore, Viagra to be produced in Pakistan represents a significant milestone for the local pharmaceutical industry. The product is expected to launch during May 2026. The company must complete all formalities before that date.

In a separate filing, AGP approved a marketing arrangement for Xanax. That product also has an expected launch timeline in May 2026 through an associated company. Additionally, AGP signed an agreement with global pharmaceutical firm STADA. The agreement covers marketing and distribution of the Oilatum skincare range in Pakistan. This reflects diversification into consumer healthcare and dermatology segments.

The board also authorized the company to explore strategic growth opportunities. These include potential acquisitions, investments, and business combinations. Operational optimization initiatives aim to improve efficiency and create synergies. AGP operates across manufacturing, marketing, and distribution of pharmaceutical products. The company often works through licensing arrangements with international partners. Incorporated in 2014, AGP continues expanding its portfolio in Pakistan.